Castle Biosciences (CSTL) CCO Juvenal Tobin Sells 1,730 Shares

What Happened Juvenal Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), sold 1,730 shares in an open-market transaction on August 17, 2026. The weighted-average sale price was $29.59 per share, for total proceeds of approximately $51,191. This was a sale (not a purchase) and thus is generally considered a routine insider disposition rather than a direct bullish signal.

Key Details

• Transaction date: August 17, 2026 (reported on Form 4 filed August 19, 2026 — timely filing)
• Trade details: 1,730 shares sold; weighted-average price $29.59; execution prices ranged $29.21–$30.01 across multiple trades
• Method: Open-market sale under a pre-established Rule 10b5-1 plan (adopted December 10, 2025)
• Shares owned after transaction: not specified in the provided excerpt of the filing
• Footnotes: F1 notes the 10b5-1 plan; F2 confirms multiple trades and offers to provide per-trade quantities/prices on request

Context A 10b5-1 plan is a pre-arranged trading plan that lets insiders sell shares on a preset schedule and is intended to reduce concerns about trading on material nonpublic information. Modest insider sales (roughly $51k here) are common and do not by themselves indicate company fundamentals; investors usually weigh such sales alongside other insider activity and company-specific news.